Itraconazol Stada (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. Without ergosterol, the fungal cell membrane becomes unstable, inhibiting growth and leading to cell death. This mechanism makes itraconazole effective against a broad range of pathogenic fungi.

The dosage of Itraconazol Stada is determined by the prescribing clinician based on the specific infection, patient weight, age, renal and hepatic function, and other clinical factors. Only a qualified health professional can set the appropriate regimen.

Safety data for itraconazole in pregnancy are limited, and the drug is generally avoided unless the benefit outweighs potential risk. It is also excreted in breast milk, so breastfeeding mothers should discuss alternatives with their health care provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itraconazole belongs to the triazole class, offering oral convenience and broad-spectrum activity. Compared with polyenes like amphotericin B, itraconazole has fewer infusion‑related reactions but shares hepatic metabolism risks. Azoles such as fluconazole have a narrower spectrum, while newer agents like voriconazole may provide better coverage for certain molds but can have higher cost.

Itraconazol Stada should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability throughout its shelf life.

The medication is taken orally, usually with a full glass of water. Depending on the formulation, it may be recommended to take it with food to improve absorption, but patients should follow the specific instructions provided by their prescriber.

Serious risks include hepatotoxicity, severe skin reactions such as Stevens‑Johnson syndrome, and worsening of heart failure. Patients should be monitored for signs of liver injury, skin changes, or cardiac symptoms, and the drug should be discontinued if these occur.

Individuals with known hypersensitivity to itraconazole or any component of the formulation should avoid the product. It is also contraindicated in patients with severe liver disease, uncontrolled heart failure, or those taking medications that cause dangerous interactions without appropriate monitoring.